Hypera SA (HYPE3)

Currency in BRL
22.20
-0.27(-1.20%)
Closed·
High dividend Yield
HYPE3 is included in our AI-picked strategies. See how they work
Fair Value
Day's Range
21.9122.50
52 wk Range
19.4130.00
Key Statistics
Bid/Ask
22.03 / 22.76
Prev. Close
22.2
Open
22.46
Day's Range
21.91-22.5
52 wk Range
19.41-30
Volume
2.36M
Average Volume (3m)
4.22M
1-Year Change
-13.3151%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
HYPE3 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
29.92
Upside
+34.76%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a low Price / Book multiple

Hypera SA News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Analyst Ratings

14 Buy
1 Hold
0 Sell
Ratings:
15 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 29.92
(+34.76% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
UBS
Buy28.50+28.38%33.00Maintain04-11-2026
JPMorgan
Buy28.00+26.13%31.00Maintain29-10-2026
JPMorgan
Buy31.00+39.64%29.00Maintain29-09-2026
Morgan Stanley
Buy32.50+46.40%31.00Maintain24-09-2026
UBS
Buy28.00+26.13%-Upgrade03-06-2026

Hypera SA Earnings Call Summary for Q3/2026

  • Hypera Pharma Q3 2026 EPS of $0.743 beat estimates by 8%, driven by lower interest expense and strong margins; revenue of 2.39B missed by 1.24%
  • New semaglutide product Semavy exceeded expectations, becoming top-selling product by October with 11% market share in injectable semaglutide segment
  • Net debt declined to 5.6B (2.0x EBITDA); company targets 1.5x leverage by end-2027 before increasing shareholder payouts and investments
  • Gross margin held steady at 61.3%; operating cash flow conversion reached 97.5% of EBITDA with working capital improving to 27% of revenue
  • October sell-out growth in low teens with Semavy driving gains; CapEx expected to fall materially in 2027 as major projects conclude
Last Updated: 28-10-2026, 09:50 pm
Read Full Transcript

Earnings

Latest Release
27-10-2026
EPS / Forecast
0.74 / 0.69
Revenue / Forecast
2.44B / 2.42B
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 2.71
Dividend Yield
4.81%
Industry Median 1.90%
Annualised payout
1.08
Paid unevenly
5-Years Growth
-32.56%
Growth Streak

HYPE3 Income Statement

Compare HYPE3 to Peers and Sector

Metrics to compare
HYPE3
Peers
Sector
Relationship
P/E Ratio
8.5x14.3x−0.2x
PEG Ratio
0.080.050.00
Price/Book
1.1x1.6x2.6x
Price / LTM Sales
1.7x1.9x2.8x
Upside (Analyst Target)
34.8%34.9%65.0%
Fair Value Upside
Unlock9.7%9.5%Unlock

Hypera S.A. operates as a pharmaceutical company in Brazil. The company provides sweeteners products under the Adocyl, finn, and Zero-cal brands; analgesics and anti-inflammatories products under the Doril, Atroveran, Calminex, Alivium, Buscopan, Buscofem, geloll, Torsilax, Neosaldina, and naprohax brands; cold and flu remedies and decongestants products under BENEGRIO, Rinosoro, Blu, Neosoro, Coristina, APRACUR, and Fluviral brands. It offers antihistamines products under Alektos, Histamin, Polaramine, PredSim, and Desrinite brands; antiseptics products under Merthiolate brand; Herbal medicine products under Maracugina, Eparema, Tamarine, and Naturetti brands; gastrointestinal products under Dramin, Estomazil, Engov, Lacto-purga, gastrol, Epocler, Bifilax, and Pepsamar brands. In addition, the company provides generics products under neo quimica brand; skicare products under episol, epidrat, simple organic, and bioage brands; supplements and vitamins products Addera, Biotonico Fontoura, Colflex, and Vitasay brands; and other products under Nebacetin, Cepacol, ESCABIN, Mirrorelax, Ammy, Nesina, and Diprospan brands. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. was founded in 1999 and is headquartered in São Paulo, Brazil.

Employees
10564
Market
Brazil

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
114.53M16.27%2.57B
Other Institutional Investors
329.51M46.80%7.40B
Public Companies & Retail Investors
259.96M36.93%5.84B
Total
703.99M100.00%15.82B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Hejoassu Administração S.A.15.78%11,10,97,48924,96,361
Maiorem S.A. de C.V13.26%9,33,71,78020,98,064

FAQ

What Is the Hypera (HYPE3) Share Price Today?

The Hypera share price today is 22.20.

What is the current Hypera (HYPE3) share price and day range?

As of 16-11-2026, the Hypera share price is 22.20, with a previous close of 22.20. The share price has ranged from 21.91 to 22.50 today, while the 52-week range spans from 19.41 to 30.00.

What Is the Hypera Market Cap?

As of today, Hypera market cap is 15.82B.

Does Hypera Pay Dividends? What's The Current Dividend Yield?

The Hypera dividend yield is 4.8%%.

What Is the Hypera (HYPE3) Share Price Target?

The average 12-month share price target for Hypera is 29.92, with a high estimate of 36 and a low estimate of 25. 14 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +34.76% Upside potential.

What Is Hypera's Earnings Per Share (TTM)?

The Hypera EPS (TTM) is 2.71.

When Is the Next Hypera Earnings Date?

Hypera will release its next earnings report on 19-02-2027.

From a Technical Analysis Perspective, Is HYPE3 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

What Stock Exchange Does Hypera Trade On?

Hypera is listed and trades on the B3 Stock Exchange.

What Is the Stock Symbol for Hypera?

The stock symbol for Hypera is "HYPE3."

How Many Times Has Hypera Stock Split?

Hypera has split 2 times.

How Many Employees Does Hypera Have?

Hypera has 10564 employees.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.